Cargando…
Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis
Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077986/ https://www.ncbi.nlm.nih.gov/pubmed/26942464 http://dx.doi.org/10.18632/oncotarget.7876 |
_version_ | 1782462282516660224 |
---|---|
author | Gu, Liangyou Li, Hongzhao Chen, Luyao Ma, Xin Li, Xintao Gao, Yu Zhang, Yu Xie, Yongpeng Zhang, Xu |
author_facet | Gu, Liangyou Li, Hongzhao Chen, Luyao Ma, Xin Li, Xintao Gao, Yu Zhang, Yu Xie, Yongpeng Zhang, Xu |
author_sort | Gu, Liangyou |
collection | PubMed |
description | Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studies were retrieved from PubMed, Embase and Web of Science databases. Overall survival (OS) was the primary outcome, cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) were secondary outcomes. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fifty-six studies comprising 20,248 patients were included in the analysis. Overall, decreased LMR was significantly associated with shorter OS in non-hematological malignancy (HR: 0.59, 95% CI: 0.53–0.66; P < 0.001) and hematological malignancy (HR: 0.44, 95% CI: 0.34–0.56; P < 0.001). Similar results were found in CSS, DFS, RFS and PFS. Moreover, low LMR was significantly associated with some clinicopathological characteristics that are indicative of poor prognosis and disease aggressiveness. By these results, we conclude that a decreased LMR implied poor prognosis in patients with cancer and could serve as a readily available and inexpensive biomarker for clinical decision. |
format | Online Article Text |
id | pubmed-5077986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50779862016-10-28 Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis Gu, Liangyou Li, Hongzhao Chen, Luyao Ma, Xin Li, Xintao Gao, Yu Zhang, Yu Xie, Yongpeng Zhang, Xu Oncotarget Research Paper Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studies were retrieved from PubMed, Embase and Web of Science databases. Overall survival (OS) was the primary outcome, cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) were secondary outcomes. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fifty-six studies comprising 20,248 patients were included in the analysis. Overall, decreased LMR was significantly associated with shorter OS in non-hematological malignancy (HR: 0.59, 95% CI: 0.53–0.66; P < 0.001) and hematological malignancy (HR: 0.44, 95% CI: 0.34–0.56; P < 0.001). Similar results were found in CSS, DFS, RFS and PFS. Moreover, low LMR was significantly associated with some clinicopathological characteristics that are indicative of poor prognosis and disease aggressiveness. By these results, we conclude that a decreased LMR implied poor prognosis in patients with cancer and could serve as a readily available and inexpensive biomarker for clinical decision. Impact Journals LLC 2016-03-03 /pmc/articles/PMC5077986/ /pubmed/26942464 http://dx.doi.org/10.18632/oncotarget.7876 Text en Copyright: © 2016 Gu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Gu, Liangyou Li, Hongzhao Chen, Luyao Ma, Xin Li, Xintao Gao, Yu Zhang, Yu Xie, Yongpeng Zhang, Xu Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title | Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title_full | Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title_fullStr | Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title_full_unstemmed | Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title_short | Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
title_sort | prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077986/ https://www.ncbi.nlm.nih.gov/pubmed/26942464 http://dx.doi.org/10.18632/oncotarget.7876 |
work_keys_str_mv | AT guliangyou prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT lihongzhao prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT chenluyao prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT maxin prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT lixintao prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT gaoyu prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT zhangyu prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT xieyongpeng prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis AT zhangxu prognosticroleoflymphocytetomonocyteratioforpatientswithcancerevidencefromasystematicreviewandmetaanalysis |